Date of Award


Degree Type

Selective Evidence-Based Medicine Review

Degree Name

Master of Science in Health Sciences - Physician Assistant


Physician Assistant Studies

Department Chair

John Cavenagh, MBA, PhD, PA-C


OBJECTIVE: The objective of this selective EBM review is to determine whether or not reslizumab is effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma.

STUDY DESIGN: This is a systematic review of three randomized controlled trials, published in peer-reviewed journals from 2015 and 2016.

DATA SOURCES: Three randomized, placebo-controlled, double-blind clinical trials comparing the effectiveness of reslizumab to a placebo in improving quality of life and asthma control. Articles were found using CINAL and PubMed databases.

OUTCOMES MEASURED: Outcomes measured include quality of life, assessed using the Asthma Quality of Life Questionnaire (AQLQ), and asthma control, assessed using the Asthma Control Questionnaire-7 (ACQ-7).

RESULTS: Bjermer et al. and Castro et al. showed significant improvement in quality of life in patients who received reslizumab compared to placebo. In Bjermer et al., 64% of patients receiving reslizumab achieved an improvement in their AQLQ score, compared to 48% for those receiving a placebo (p=0.0189). In Castro et al., 74% of patients receiving reslizumab had an improvement in their AQLQ score, compared to 65% of those receiving a placebo (p=0.03). Corren et al. showed a significant improvement in asthma control, with 71% of patients receiving reslizumab having improvement, compared to 57% of patients in the control group (p=0.01).

CONCLUSION: Reslizumab is an effective treatment to improve quality of life and asthma control in patients with inadequately controlled eosinophilic asthma.